Cancer systems biology: Embracing complexity to develop better anticancer therapeutic strategies

Oncogene

Volumn 34, Issue 25, 2015, Pages 3215-3225

  Du, W ^a   Elemento, O ^a  

^a Laboratory of Cancer Systems Biology Department of Physiology and Biophysics Institute for Computational Biomedicine and Institute for Precision Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL MODEL; CANCER CELL; CANCER RESEARCH; CANCER THERAPY; CELL POPULATION; GENOME; GENOMICS; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEXT GENERATION SEQUENCING; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN PROCESSING; SYSTEMS BIOLOGY; TISSUE LEVEL; TUMOR GROWTH; ANIMAL; DRUG DEVELOPMENT; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES; TRENDS;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; SYSTEMS BIOLOGY;

EID: 84931569174     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.291     Document Type: Article

References (139)

1. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228.
2. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-1558.
4. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013; 339: 1567-1570.
5. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437.
6. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
7. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32: 40-51.
8. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.
9. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011; 480: 387-390.
10. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009; 106: 20411-20416.
11. The Cancer Genome Atlas Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-49.
12. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527.
13. Casado P, Rodriguez-Prados JC, Cosulich SC, Guichard S, Vanhaesebroeck B, Joel S et al. Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci Signal 2013; 6: rs6.
14. Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L et al. Profiles of basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci Signal 2013; 6: ra84.
15. Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal 2013; 6: ra68.
16. Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D et al. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol 2013; 9: 673.
17. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 2009; 69: 6713-6720.
18. Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA et al. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 2014; 156: 603-616.
19. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 2014; 6: 514-527.
20. Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R et al. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat Genet 2012; 44: 1207-1214.
21. Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform 2013; 11: 164-173.
22. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 5400-5413.
23. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-1266.
24. Pan H, Jiang Y, Redmond D, Nie K, Cerchietti L, Shaknovich R et al. Epigenomic evolution in diffuse large B-cell lymphomas. Blood 2013; 122: 634-634.
25. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 2013; 3: 2650.
26. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145: 30-38.
27. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012; 488: 337-342.
28. McFarland CD, Korolev KS, Kryukov GV, Sunyaev SR, Mirny LA. Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci USA 2013; 110: 2910-2915.
29. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
30. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
31. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-477.
32. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485: 502-506.
33. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013; 5: 197ra101.
34. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-334.
35. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
36. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110: 4009-4014.
37. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013; 231: 21-34.
38. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225-233.
39. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
40. Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer 2014; 14: 371-380.
41. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014; 508: 113-117.
42. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
43. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
44. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
45. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014; 343: 189-193.
46. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339: 543-548.
47. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci USA 2007; 104: 19914-19919.
48. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
49. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010; 11: 31-46.
50. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
51. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506: 371-375.
52. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y et al. Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-677.
53. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
54. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
55. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-1031.
56. Pike BL, Greiner TC, Wang X, Weisenburger DD, Hsu YH, Renaud G et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 2008; 22: 1035-1043.
57. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011; 21: 1028-1041.
58. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012; 44: 40-46.
59. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res 2012; 22: 246-258.
60. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43: 768-775.
61. Booth MJ, Branco MR, Ficz G, Oxley D, Krueger F, Reik W et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012; 336: 934-937.
62. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013; 32: 663-669.
63. Eswaran J, Cyanam D, Mudvari P, Reddy SD, Pakala SB, Nair SS et al. Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep 2012; 2: 264.
64. Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S et al. Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep 2013; 3: 2256.
65. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.
66. Eswaran J, Horvath A, Godbole S, Reddy SD, Mudvari P, Ohshiro K et al. RNA sequencing of cancer reveals novel splicing alterations. Sci Rep 2013; 3: 1689.
67. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-94.
68. Xu X, Hou Y, Yin X, Bao L, Tang A, Song L et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012; 148: 886-895.
69. Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012; 148: 873-885.
70. Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 2011; 29: 1120-1127.
71. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
72. Vandin F, Upfal E, Raphael BJ. Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol 2011; 18: 507-522.
73. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J et al. Inference of patientspecific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010; 26: i237-i245.
74. Hu J, Locasale JW, Bielas JH, O'Sullivan J, Sheahan K, Cantley LC et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol 2013; 31: 522-529.
75. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-1133.
76. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
77. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
78. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
79. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-9996.
80. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 2012; 18: 2032-2038.
81. Cheng WY, Ou Yang TH, Anastassiou D. Development of a prognostic model for breast cancer survival in an open challenge environment. Sci Transl Med 2013; 5: 181ra150.
82. Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH et al. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med 2013; 5: 181re181.
83. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
84. Basanta D, Gatenby RA, Anderson AR. Exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol Pharm 2012; 9: 914-921.
85. Reth M, Brummer T. Feedback regulation of lymphocyte signalling. Nat Rev Immunol 2004; 4: 269-277.
86. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
87. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-1654.
88. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
89. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
90. Pierobon M, Wulfkuhle J, Liotta L, Petricoin E. Application of molecular technologies for phosphoproteomic analysis of clinical samples. Oncogene 2015; 34: 805-814.
91. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006; 127: 635-648.
92. Moritz A, Li Y, Guo A, Villen J, Wang Y, MacNeill J et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 2010; 3: ra64.
93. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011; 332: 687-696.
94. Spurrier B, Ramalingam S, Nishizuka S. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 2008; 3: 1796-1808.
95. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
96. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr. Dayyani F et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-667.
97. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012; 11: 909-920.
98. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
99. Wagner JP, Wolf-Yadlin A, Sevecka M, Grenier JK, Root DE, Lauffenburger DA et al. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci Signal 2013; 6: ra58.
100. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011; 30: 4567-4577.
101. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379.
102. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23: 277-286.
103. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
104. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
105. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
106. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
107. Sheehan KM, Gulmann C, Eichler GS, Weinstein JN, Barrett HL, Kay EW et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 2008; 27: 323-331.
108. Kahlert C, Pecqueux M, Halama N, Dienemann H, Muley T, Pfannschmidt J et al. Tumour-site-dependent expression profile of angiogenic factors in tumourassociated stroma of primary colorectal cancer and metastases. Br J Cancer 2014; 110: 441-449.
109. Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB et al. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci USA 2011; 108: 17456-17461.
110. Wu Y, Zhang W, Li J, Zhang Y. Optical imaging of tumor microenvironment. Am J Nucl Med Mol Imaging 2013; 3: 1-15.
111. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012; 21: 488-503.
112. Wang Y, Zhou K, Huang G, Hensley C, Huang X, Ma X et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat Mater 2014; 13: 204-212.
113. Vakoc BJ, Lanning RM, Tyrrell JA, Padera TP, Bartlett LA, Stylianopoulos T et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 2009; 15: 1219-1223.
114. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500-504.
115. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer 2007; 121: 1463-1472.
116. Wu Y, Lu Y, Chen W, Fu J, Fan R. In silico experimentation of glioma microenvironment development and anti-tumor therapy. PLoS Comput Biol 2012; 8: e1002355.
117. Eikenberry S, Thalhauser C, Kuang Y. Tumor-immune interaction, surgical treatment, and cancer recurrence in a mathematical model of melanoma. PLoS Comput Biol 2009; 5: e1000362.
118. Oved K, Eden E, Akerman M, Noy R, Wolchinsky R, Izhaki O et al. Predicting and controlling the reactivity of immune cell populations against cancer. Mol Syst Biol 2009; 5: 265.
119. Venkatasubramanian R, Arenas RB, Henson MA, Forbes NS. Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response. Br J Cancer 2010; 103: 486-497.
120. Choe SC, Zhao G, Zhao Z, Rosenblatt JD, Cho HM, Shin SU et al. Model for in vivo progression of tumors based on co-evolving cell population and vasculature. Sci Rep 2011; 1:31.
121. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-265.
122. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
123. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011; 8: 135-141.
124. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
125. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
126. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
127. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
128. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
129. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
130. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffinembedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20: 682-688.
131. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
132. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
133. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013; 3: 1364-1377.
134. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19: 1389-1400.
135. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra121.
136. Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 2014.
137. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
138. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbhandari P et al. Genomewide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 2009; 27: 829-839.
139. Karr JR, Sanghvi JC, Macklin DN, Gutschow MV, Jacobs JM, Bolival B Jr. et al. A whole-cell computational model predicts phenotype from genotype. Cell 2012; 150: 389-401.